Anticancer Drugs
O'Boyle, Niamh M
Anticancer Drugs - MDPI - Multidisciplinary Digital Publishing Institute 2019 - 1 electronic resource (214 p.)
Open Access
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody-drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
Creative Commons
English
books978-3-03921-587-4 9783039215867 9783039215874
10.3390/books978-3-03921-587-4 doi
graphene oxide indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance
Anticancer Drugs - MDPI - Multidisciplinary Digital Publishing Institute 2019 - 1 electronic resource (214 p.)
Open Access
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody-drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
Creative Commons
English
books978-3-03921-587-4 9783039215867 9783039215874
10.3390/books978-3-03921-587-4 doi
graphene oxide indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance